Search research articles
Contact Us
Filters
Showing results (81-90 of 99) with videos related to
Page
of 10
Sort By:
Current Vascular Pharmacology
|
May 21, 2011
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary
Dimitri P Mikhailidis, Moses Elisaf, Manfredi Rizzo, et al.
Current Vascular Pharmacology
|
May 21, 2011
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses
Dimitri P Mikhailidis, Moses Elisaf, Manfredi Rizzo, et al.
Atherosclerosis
|
June 1, 2022
The spoils of war and the long-term spoiling of health conditions of entire nations
Eliano P Navarese, Klaudyna Grzelakowska, Francesco Mangini, et al.
European Heart Journal Supplements : Journal of the European Society of Cardiology
|
May 24, 2017
Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia
Roberto Ferrari, Carlos Aguiar, Eduardo Alegria, et al.
Atherosclerosis. Supplements
|
August 29, 2015
A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy
Carlos Aguiar, Eduardo Alegria, Riccardo C Bonadonna, et al.
The American Journal of Cardiology
|
December 17, 2008
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia
Jean-Charles Fruchart, Frank Sacks, Michel P Hermans, et al.
Atherosclerosis Plus
|
November 13, 2024
A collaborative effort across Africa to investigate risk factors and outcomes of premature acute coronary syndrome: Protocol for the EAS Lipid Registry of Africa (LIPRA)
Ashraf Reda, Alexander R M Lyons, Alberto Zambon, et al.
Diabetes & Vascular Disease Research
|
October 30, 2008
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient
Jean-Charles Fruchart, Frank M Sacks, Michel P Hermans, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]
|
March 14, 2026
Clinical outcomes of hypertriglyceridemia-associated acute pancreatitis: a prospective multicenter Italian cohort
Giulia De Marchi, Nicolò de Pretis, Gabriele Capurso, et al.
Giornale Italiano Di Cardiologia (2006)
|
March 24, 2020
[Appropriateness criteria for the management of lipid-lowering therapy with alirocumab in high cardiovascular risk patients. The opinion of a multidisciplinary group of Italian experts]
Maddalena Lettino, Alberto Zambon, Giuseppe Musumeci, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 99) with videos related to
Sort By:
Page
of 10
Current Vascular Pharmacology
|
May 21, 2011
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary
Dimitri P Mikhailidis, Moses Elisaf, Manfredi Rizzo, et al.
Current Vascular Pharmacology
|
May 21, 2011
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses
Dimitri P Mikhailidis, Moses Elisaf, Manfredi Rizzo, et al.
Atherosclerosis
|
June 1, 2022
The spoils of war and the long-term spoiling of health conditions of entire nations
Eliano P Navarese, Klaudyna Grzelakowska, Francesco Mangini, et al.
European Heart Journal Supplements : Journal of the European Society of Cardiology
|
May 24, 2017
Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia
Roberto Ferrari, Carlos Aguiar, Eduardo Alegria, et al.
Atherosclerosis. Supplements
|
August 29, 2015
A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy
Carlos Aguiar, Eduardo Alegria, Riccardo C Bonadonna, et al.
The American Journal of Cardiology
|
December 17, 2008
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia
Jean-Charles Fruchart, Frank Sacks, Michel P Hermans, et al.
Atherosclerosis Plus
|
November 13, 2024
A collaborative effort across Africa to investigate risk factors and outcomes of premature acute coronary syndrome: Protocol for the EAS Lipid Registry of Africa (LIPRA)
Ashraf Reda, Alexander R M Lyons, Alberto Zambon, et al.
Diabetes & Vascular Disease Research
|
October 30, 2008
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient
Jean-Charles Fruchart, Frank M Sacks, Michel P Hermans, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]
|
March 14, 2026
Clinical outcomes of hypertriglyceridemia-associated acute pancreatitis: a prospective multicenter Italian cohort
Giulia De Marchi, Nicolò de Pretis, Gabriele Capurso, et al.
Giornale Italiano Di Cardiologia (2006)
|
March 24, 2020
[Appropriateness criteria for the management of lipid-lowering therapy with alirocumab in high cardiovascular risk patients. The opinion of a multidisciplinary group of Italian experts]
Maddalena Lettino, Alberto Zambon, Giuseppe Musumeci, et al.
Page
of 10